Zacks Research Brokers Lift Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities research analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for Surmodics in a research note issued on Monday, November 25th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.14 per share for the year, up from their prior estimate of $0.13. The consensus estimate for Surmodics' current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at $0.21 EPS, Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.20 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.81 EPS.

A number of other equities analysts have also issued reports on the company. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a report on Thursday, November 7th. StockNews.com initiated coverage on Surmodics in a report on Saturday. They set a "hold" rating on the stock. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Surmodics currently has a consensus rating of "Hold" and an average target price of $50.00.

Surmodics Stock Performance

Shares of SRDX traded down $0.04 during midday trading on Wednesday, reaching $39.54. 120,025 shares of the stock were exchanged, compared to its average volume of 228,987. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.96 and a quick ratio of 3.22. Surmodics has a twelve month low of $25.17 and a twelve month high of $42.44. The business's 50-day moving average price is $38.50 and its 200 day moving average price is $39.58. The company has a market capitalization of $566.61 million, a price-to-earnings ratio of -48.65 and a beta of 1.20.

Surmodics (NASDAQ:SRDX - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.14. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%. The business had revenue of $33.23 million for the quarter, compared to analysts' expectations of $30.69 million.

Institutional Investors Weigh In On Surmodics

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Surmodics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 865,214 shares of the company's stock valued at $25,385,000 after acquiring an additional 5,927 shares during the period. Renaissance Technologies LLC lifted its position in shares of Surmodics by 5.0% during the 2nd quarter. Renaissance Technologies LLC now owns 606,538 shares of the company's stock valued at $25,499,000 after acquiring an additional 28,990 shares during the period. State Street Corp lifted its position in shares of Surmodics by 19.2% during the 3rd quarter. State Street Corp now owns 374,068 shares of the company's stock valued at $14,506,000 after acquiring an additional 60,240 shares during the period. Gabelli Funds LLC lifted its position in shares of Surmodics by 393.7% during the 2nd quarter. Gabelli Funds LLC now owns 260,200 shares of the company's stock valued at $10,939,000 after acquiring an additional 207,500 shares during the period. Finally, Gardner Lewis Asset Management L P acquired a new stake in shares of Surmodics during the 2nd quarter valued at approximately $8,531,000. Hedge funds and other institutional investors own 96.63% of the company's stock.

Insider Buying and Selling at Surmodics

In other Surmodics news, CFO Timothy J. Arens sold 7,009 shares of Surmodics stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total value of $276,434.96. Following the sale, the chief financial officer now owns 70,350 shares of the company's stock, valued at approximately $2,774,604. The trade was a 9.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.90% of the stock is owned by corporate insiders.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).